- Home
- JFR vs TNDM Comparison
JFR vs TNDM Comparison
Compare JFR & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JFR
- TNDM
- Stock Information
- Founded
- JFR 2004
- TNDM 2006
- Country
- JFR United States
- TNDM United States
- Employees
- JFR N/A
- TNDM N/A
- Industry
- JFR Trusts Except Educational Religious and Charitable
- TNDM Medical/Dental Instruments
- Sector
- JFR Finance
- TNDM Health Care
- Exchange
- JFR Nasdaq
- TNDM Nasdaq
- Market Cap
- JFR 1.1B
- TNDM 1.1B
- IPO Year
- JFR N/A
- TNDM 2013
- Fundamental
- Price
- JFR $8.42
- TNDM $11.74
- Analyst Decision
- JFR
- TNDM Buy
- Analyst Count
- JFR 0
- TNDM 15
- Target Price
- JFR N/A
- TNDM $23.60
- AVG Volume (30 Days)
- JFR 621.7K
- TNDM 2.8M
- Earning Date
- JFR 01-01-0001
- TNDM 08-06-2025
- Dividend Yield
- JFR 11.31%
- TNDM N/A
- EPS Growth
- JFR N/A
- TNDM N/A
- EPS
- JFR N/A
- TNDM N/A
- Revenue
- JFR N/A
- TNDM $1,001,719,000.00
- Revenue This Year
- JFR N/A
- TNDM $8.91
- Revenue Next Year
- JFR N/A
- TNDM $10.94
- P/E Ratio
- JFR N/A
- TNDM N/A
- Revenue Growth
- JFR N/A
- TNDM 25.84
- 52 Week Low
- JFR $7.61
- TNDM $9.98
- 52 Week High
- JFR $8.82
- TNDM $47.60
- Technical
- Relative Strength Index (RSI)
- JFR 50.40
- TNDM 42.90
- Support Level
- JFR $8.39
- TNDM $10.25
- Resistance Level
- JFR $8.53
- TNDM $12.74
- Average True Range (ATR)
- JFR 0.05
- TNDM 0.60
- MACD
- JFR -0.00
- TNDM 0.32
- Stochastic Oscillator
- JFR 50.00
- TNDM 80.80
About JFR Nuveen Floating Rate Income Fund
Nuveen Floating Rate Income Fund is a diversified closed-end management investment company. Its investment objective is to achieve a high level of current income, consistent with the preservation of capital. It invests in adjustable-rate U.S. dollar-denominated secured Senior Loans.
About TNDM Tandem Diabetes Care Inc.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.